Treatment Flashcards
First and second line treatment for neisseria gonorrhoea
1st: stat IM ceftriaxone
2nd: Stat Cefixime 400mg PLUS azithro 2g Stat IM gent 240mg PLUS azithro 2g Stat IM spectinomycin 2g PLUS azithro 2g Potentially ofloxacillin
Treatment of gonorrhoea in pregnancy
Stat IM ceftriaxone OR Stat IM spectinomycin 2g OR Stat azithromycin 2g
2nd line trichomonas vaginalis treatment
Metronidazole 2g stat
OR
Tinidazole 2g Stat
Persistent trichomonas vaginalis
Repeat metronidazole 400mg BD 7d
Then:
High dose metronidazole or tinidazole 2g daily for 5-7d
Then -> resistance testing
Then:
Tinidazole 1g BD/TDS for 14/7 or 2g BD 14/7
Which HSV virus most likely to cause recurrent anogenital symptoms?
HSV-2
Median recurrence rate for HSV-2?
Approx 4 times per year
When are oral antiviral indicated for herpes?
Within 5 days start of episode, whilst new lesions are still forming or if systeic symptoms persist
Preferred treatment for herpes:
Aciclovir 400mg TDS
Valaciclovir 500mg BD
Alternative treatment for herpes:
Aciclovir 200mg 5x/day
Famciclovir 250mg TDS
First line for episodic management of recurrent herpes:
Aciclovir 800mg TDS 2days
Famciclovir 1g BD 1 day
Valaciclovir 500mg BD 3 days
Longer course for episodic management of recurrent herpes:
Aciclovir 200mg 5x day 5 days
aciclovir 400mg TDS 3-5 days
Valaciclovir 500mg BD 5 days
Famciclovir 125mg BD 5 days
Recommended HSV suppresive treatment? (Getting at least 6 episodes a year)
Aciclovir 400mg BD
Aciclovir 200mg 4X day
Famciclovir 250mg BD
Valaciclovir 500mg OD
What to discsus with patients about herpes transmission:
Abstinence from sex when prodrome/lesions
Transmission may occur as result of asymptomatic shedding
Condoms reduce risk but cannot prevent it
Discloure is advised in all relationships (document these discussions)
Reassure cannot be transmitted by towels/sheets etc.
Ensure do not transfer to someone pregnant
Preventing HSV transmission to a pregnant partner:
Use condoms, especially last trimester
Abstain from sex at time of lesion recurrent
Abstani from sex in last 6 weeks pregnancy
If partner has history of oro-facial HSV, avoid oral sex
First episode genital herpes when pregnant, who can have vaginal delivery?
Providing delivery does not occur in the next 6 weeks, vaginal delivery can be expected.
Following first or second trimester genital herpes acquistion, when to start suppresive treatment?
From 36 weeks start daily suppressive aciclovir 400mg TDS
If first episode genital herpes acquired in third trimester:
Aciclovir 400mg TDS should be started and continued until delivery, C-secton should be the recommended mode of delivery. (If within 6 weeks of delivery, risk of neonatal herpes as high as 41%).
HSV IgG serology should be taken, if same as isolated on swab then is a recurrence
If woman has first episode genital herpes in third trimester but wants a vaginal delivery:
IV aciclovir 5mg/kg TDS, and then neonate 20mg/kg TDS. Aim to avoid invasive procedures.
Most common of the serovars causing LGV
L2 most common (L2b most common, of L1/L2/L3)
Stages of LGV:
‘Classical LGV’ has 1st stage of papule/ulcer, 2nd stage lymphadenopathy/buboes, 3rd stage chronic inflammatory disease with fistulae/strictures etc. In the MSM outbreak, most present at with primary manifestation of direct infection of rectal mucosa with proctitis
Diagnosis of LGV:
- NAATS, if LGV suspected then PCR looking for LGV specific DNA.
- On microscopy >10 PMNLs per high power field
- Culture on cycloheximide treated McCoy cells
- Chlamydia serology: in general a 4 fold rise in antibody OR single point titre of >1/64 have been considered positive for LGV (lacks sensitivity for earlier infections)
General advice for LGV:
- Bacterial STI that is curable with antibiotics but left untreated can have serious and permanent adverse features
- Symptoms should resolve in 1-2 weeks of Rx
- Avoid unprotected sex until they and partners have completed Rx and FU
- High rates of HIV and HCV infection are observed, discuss risk reductoni such as avoiding UPSI, avoiding traumatic anorectal practices such as fisting or sex toy use, or shared equipment for douching
1st and 2nd line treatment for LGV:
1) Doxycycline 100mg BD for 3 weeks (or tetracycline 2g daily, or minocycline 300mg loading then 200mg BD)
2) Erythromycin 500mg QDS for 3 weeks (first choice in pregnant or breast feeding), or azithromycin 1g weekly
(single case of doxy failure, responded to moxifloxacin 400mg daily 10 days)
When to do TOC in LGV?
Do TOC 2 weeks after completion of treatment if anything but doxycycline was used.
LGV partner notifcaiton and contact tracing:
Anyone that had sexual contact with patient within 4 weeks of onset of symptoms or last 3 months if asymptomatic should be examined, tested and presumptively treated with 3 weeks treatment.
Follow up for LGV:
Follow up until signs/symptoms have resolved, usually takes 1-2 weeks, can take 3-6 if londstanding. Routine TOC not usually required,
What microbe causes Chancroid?
Haemophilus Ducreyi - gram negative facultative anaerobic coccobacillus
Clinical features of Chancroid
Anogenital ulceration and lymphadenitis with progression to bubo formation.
Incubation period 4-7 days
Lesions start as a tender papule then pustule then ulcer or soft sore.
Typically ulcers have a ragged undermined edge with grey/yellow base that bleeds when touched.
Lesions are painful, single or multiple
Diagnosis of H. ducreyi
- PCR but rarely available
- Culture obtained from ulcer base, grown in high humidity with 5% carbon dioxide, culture media include GC Agar supplemented with bovine haemoglobin, fetal calf serum. Or Mueller-Hinton agar with chocolatised horse blood. Or activated charcoal instead of metal calf serum.
- Sensitivity still only around 80%
- Microscopy only 50% sensitive
Recommended regimen for Chancroid
- Azithromycin 1g orally single dose
- ceftriaxone 250mg IM single dose
- Ciprofloxacin 500mg BD for 3 days
- Erythromycin 500mg QDS for 7 days
(Use cipro or erythromycin if HIV positive)
(erythro or ceftriaxone if pregnant)
Follow up and PN for chancroid
- Re-examine in 3-7 days to see if ulcers are improving. LN may take longer.
- TOC not recommended
- Those with sexual contact 10 days before should be examined and treated even if absent of symptoms
Causative organism for Donovanosis
- Originally Calymmatobacterium granulomatis
- Proposal to reclassify as Klebsiella granulomatis comb nov.
Clinical features of Donovanosis.
Genitals are affected in 90%, inguinal area 10%, rarely extrangenital.
Lymphadenitis is uncommon
SCC can mimic and complicate donovonosis, biopsy should follow if Abc fail.
Four types described:
- Ulcerogranulomatous most common- non tender, fleshy. single or multiple red ulcers that bleed when touched
- Hypertrophic or verrous type
- Nectrotic, deep and foul smelling ulcer
- Sclerotic with extensive fibrous tissue
Diagnosis of donovonosis
- Direct microscopy (Giemsa or silver stain best): quickest and most reliable -> large mononuclear cells with intracytoplasmic cysts filled with deeply-stained Gram negative Donovan bodies
- PCR for C. granulomatis (nil commercially available)
- Culture not routinely available
Management of donovanosis
Following for 3 weeks or until lesions completely healed:
- Azithromycin 1g weekly (or 500mg daily)
- Septrin 160/800mg BD orally
- Doxycyline 100mg BD orally
- Erythromycin 500mg QDS (if pregnant)
- Gentamicin 1mg/kg 8 hourly IV if lesions slow to respond
Children: azithro 20mg/kg OD), consider prophylaxis in neonates born to mothers with lesions (for 3d)
Follow up and PN for donovanosis
Check for lesions in all partners for prior 6 months
Follow patient up until lesions resolved
Molluscum infection caused by:
- Molluscum contagiosum, a large DNA virus belonging to Poxviridae family
- Up to 4 subtypes identified, MCV-1 most common
- No big difference between the types, MCV-2 relatively more common in the immunocompromised
Most common settings molluscum occurs:
- Through routine physical contact or occasionally formats, children account for 90% infections, often face, neck, trunk, limbs
- As an STI in young adults, genitals/pubic regions/thighs/buttocks
- Severe molluscum in setting immunocompromised
Clinical features of molluscum contagiosum:
- Characteristically smooth surfaced, firm, dome shaped papules with central umbilication
- Pearly white, pink to yellow
- Usually 2-5mm, unless immunocompromised
- Commonly 1-30 lesions occurring as clusters
- Usually asymptotic, sometimes itchy
- In the immunocompromised can see 100 or more lesions and can coalesce.
Diagnosis of molluscum:
- Usually clinical
- Differential includes BCC, cysts, abscesses, genital warts, disseminated fungal infections
Genera advice for management of molluscum:
General advice:
- Warned of risks of autoinoculation, advised against shaving/waxing genitals, advise against squeezing
- Don’t share formats whilst active lesions
- If swimming, cover areas if possible
- Condoms can reduce transmission but not absolute
- If genital, do full STI screen
- Exclude disseminated fungal infection if immunocompromised
Treatment of molluscum:
- No treated is recommended if immunocompetent , usually resolve with no sequelae.
- If patient wants treatment, advise new lesions may continue to form
- Podophyllotoxin BD for 3d then 4d pause, for 4 weeks if necessary
- Imiquimod 5% M, W, F, washed off 6-10 hours later, for up to 16 weeks (has demonstrated some limited efficacy in HIV positive and negative)
- Liquid nitrogen has been used, but no trials
- Curettage not suitable for genital lesions, and evidence for efficacy on other lesions is sparse
- Pregnancy: cryotherapy, avoid podophylotoxin or imiquimid
- HIV: topical cidofovir has some efficacy in non genital lesions not improving (causes inflammation so not for genital)
- PN not required
General advice for all vulval conditions:
- Avoid contact with soap, shampoo or bubble bath
- Simple emollients can be used as soap substitutes
- Avoid tight fitting garments which may irritate the area
- Avoid use of spermicidally lubricated condoms
- Detailed explanation of their condition etc.
- Inform GP
- Consider STI screen if itch
- Assess for sexual dysfunction
Vulval lichen sclerosus- aetiology and clinical features
- Inflammatory disorder of unknown aetiology but thought to be autoimmune factors (increased frequency of other autoimmune disorders in females with LS)
- Often in women over age 50
- Extracellular matrix 1 (ECM1) antibodies in 60-80%
- Symptoms: itch, soreness, dyspareunia, urinary symptoms, constipation if anal invovlement
- Signs: pale, atrophic areas affecting the vulva (non hair bearing areas) never involves vaginal mucosa, purpura is common, fissuring, erosions, hyperkeratosis, loss of architecture e.g. loss of labia minora, clitoral hood may be sealed over clitoris
- 10% may have extra-genital lesions, pale white plaques of atrophic, thin skin
Complications of lichen sclerosus
- SCC (<5 %)
- Clitoral pseudo cyst
- Sexual dysfunction
Diagnosis of LS:
- Characteristic appearance
- Vulval biopsy: epidermal atrophy, hyperkeratosis with sub-epidermal hyalinisation of collagen and lichenoid infiltrate
- Biopsy mandatory if Dx uncertain or atypical features that could be VIN/SCC (reasonable to trial steroids with no biopsy if features are typical)
- Ix for autoimmune disease if clinically indicated, e.g. TFTs
- Skin swab if secondary infection suspected
Management of LS:
- General advice: written info, and aware of small risk neoplastic change, advised to contact doctor if see a change e.g. lump or hardening of skin. Often a chronic condition needing long term follow up
- Recommended regimen (ointment bases are best):
1) Ultra-potent topical steroid (e.g. clobetasol proprionate/’Dermovate’) e.g. daily for one month, alternate days one month, 3x week 1 month then review at 3 months
2) Altenative regimens may contain antibac/antifungal as well (e.g. dermovate NN, fucibet)
3) Unlicensed treatments: topical tacrolimus, oral retinoids e.g. acitretin, UVA phototherapy
1) is safe in pregnancy and breastfeeding, rest are not
Calculation for risk of HIV transmission:
Risk that source is HIV positive x risk of exposure
Factors affecting PEP efficacy:
- Delayed initiation
- Transmission of resistant virus
- Variable genital tract drug penetration
- Poor/non-adherence
- Further high risk sexual exposures
Factors increasing risk of HIV transmission:
- High plasma VL in the source
- Breaches in the mucosal barrier e.g. trauma or ulcers
- Menstruation - theoretical risk
- Ejaculation - increased risk
- STIs
- Non-circumcision
- Discordant HIV VL in the genital tract
Thresholds used for PEPSE initiation
Transmission risk:
> 1 in 1000 -> PEPSE recommended
Between 1 in 1000 and 1 in 10,000 -> consider (give if additional factors that increase risk transmission)
<1 in 10,000 -> not recommended
Items to discuss with person starting PEPSE:
- The rationale for using PEPSE ‘reduce dissemination and replication in all tissues’
- Lack of conclusive data for efficacy
- Potential risks and side effects
- Arrangement for early follow up
- Pre test discussion an 4th gen HIV test
- The need to continue for 28 days if baseline negative
- The need for follow up HIV test 8-12 weeks after
- The need for safer sex for next 2 months
- EC if relevant
- Vaccinations
- U+E, LFT, UPCR, hep screen
- Coping strategies, social support
- Sexual health advisor +/- psychology
Recommended and alternative PEPSE:
Recommended: Truvada (1 tablet OD) + raltegravir (400mg BD) (avoid antacids and MVT with raltegravir)
Alternative backbone: Combivir (zidovudine + lamivudine)
Alternative 3rd agent: kaletra/darunavir/atazanavir/folutegravir
Recommended monitoring during PEP course:
Baseline: Creatinine, ALT, urinalysis, UPCR, HIV, hepBsAg, STS/hep C/Hep B (as per local guidelines), STI testing, pregnancy test, CK (if symptoms myositis)
2 weeks: STI testing, renal/liver ONLY if abnormalities at baseline
8-12 weeks post: HIV, STS, STI if further UPSI, renal/liver ONLY if abnormalities previously
Guidance on missed doses of PEPSE:
<24 hours since last dose: take missed dose immediately and subsequent dose at normal time
24-48 hours sine last dose: continue PEPSE
>48 hours since last dose: stop PEPSE
Diagnosis of scabies:
1) Mostly clinical: Hx intense itch, worse at night, other members affected, skin burrows, erythematous papules in webspace, flexor aspect wrists, extensor aspects elbows, umbilicus/buttocks, feet etc. (spares the scalp) NB. it is a hypersensitivity rash occurring 4-6 weeks after infestation, few days if re-exposed
2) Dermatoscopy - mite at end of burrow
3) Microscopic identification of the mites, eggs or faecal pellets (scrape skin with scalpel blade and place on glass slide with 10% potassium hydroxide)
4) Burrow ink test
Treatment of scabies:
General advice: bedding/clothing/towels used by person or their household/sexual/close contact in 4 days before treatment hot washed 60 degrees/dry-cleaning/sealing in plastic for 72 hours. Itching may continue for 2-4 weeks (can try crotamiton 10% cream)
Recommended: Permethrin 5% cream- whole body from chin/ears down (unless young/immunocompromised/elderly then include face and scalp). Apply to cool, dry skin. Allow to dry before dressing. Wash off after 8-12 hours. Reapply 1 week later. Treat hands again if wash them with soap within 8hours. Ok pregnancy and breastfeeding (wash off nipple)
Alternative: Malathion 0.5% aqueous lotion (use if e.g. allergy to chrysanthemums so can’t have permethrin), same application process as above, but wash off after 24 hours. Reapply in 1 weeks.
Alternative: Ivermectin 200mcg/kg 2 weeks apart in patients weighing >15kg. Used if crusted scabies don’t respond to topical, can cause nausea/vomiting/abdo pain, low risk in pregnancy
Treatment of crusted scabies:
Topical permethrin cream one daily for 7 days, then twice weekly until cure
Plus - oral ivermectin (200mcg/kg) on days 1, 2, 8, 9, 15
Isolate immediately, barrier nursing.
All household members treated at same time
Contact tracing for scabies
Current sexual partners and household contacts/other close contacts should be examined and treated at same time.
Contact tracing of partners from the previous month
If still symptomatic after 2 weeks or burrows seen, consider re-treatment, use a different regimen
Transmission of public lice (Pediculosis pubis, or pthirus pubis):
- Usually skin to skin, up to 95% sexual contacts of a carrier will develop infestation
- occasionally by formats
- unlikely lice can survive more than 24-48 hours if removed from host
Clinical features of pediculosis pubis:
- Itch
- Erythema
- Infestation of eye lashes (pediculosis Claris) and eyebrows can occur, where can cause a severe blepharoconjunctivitis
- Blue macule may be visible at feeding sites
- ‘Black spots’ may be seen on underwear and are faecal matter or blood spots
- Concomitant STIs present in 30%
- Incubation period 5 days to several weeks
Management of pubic lice:
- Avoid close contact until pt and partner treated
- Contact trace to 3 months, and also those than share bedding
- Hot wash or dry clean bed linen
- Full STI screen
- re-examine 1 week after treatment, give an alternative treatment if treatment failure. Dead nits may remain, can be removed with a comb
- Lotions are likely to be more effective than shampoos and should be applied to all body hair.
- Second application in 3-7 days advised
- Suggested treatments:
- > Permethrin 1% cream rinse (a pyrethroid, apply to damp hair and wash out after 10 mins)
- > Malathion 0.5% (an organophosphate, apply to dry hair, leave 2-12 hours and wash out)
- > Phenothrin 0.2% (also pyrethroid, apply to dry hair and wash out after 2 hours)
- > Carbaryl 0.5 and 1% (apply to dry hair and wash out 12 hours later)
- > Ivermectin PO considered in resistant cases
Pregnancy + breastfeeding: permethrin is safe